Fig. 4: Gemcitabine treatment induces IGF1 signaling and binding of transcription factors p-cJun, Ets1, and Egr1 to CD44 promoter. | Cell Death & Disease

Fig. 4: Gemcitabine treatment induces IGF1 signaling and binding of transcription factors p-cJun, Ets1, and Egr1 to CD44 promoter.

From: Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching

Fig. 4

a GS cells were treated with gemcitabine for the indicated period. EGFR, IGFR phosphorylation, and transcription factor p-cJun, Ets1, and Egr1 were detected by Western blot analysis. b GS cells were treated with gemcitabine for 48 h and chromatin immunoprecipitation assays were performed. The binding of p-cJun, Ets1, and Egr1 to CD44 promoter was analyzed by regular PCR (upper panel) and by quantitative PCR (lower panel). Fold enrichments are represented as signals obtained from immunoprecipitation with specific antibodies relative to signals obtained from immunoprecipitation with control IgG (mean ± SD from triplicate).

Back to article page